US 12,233,058 B2
Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine
Jaikrishna Patel, Cary, NC (US); and Paul Chamberlin, Brookline, MA (US)
Assigned to IMBRIA PHARMACEUTICALS, INC., Boston, MA (US)
Filed by IMBRIA PHARMACEUTICALS, INC., Boston, MA (US)
Filed on Jun. 23, 2023, as Appl. No. 18/213,407.
Application 18/213,407 is a division of application No. 17/540,657, filed on Dec. 2, 2021, granted, now 11,730,733.
Claims priority of provisional application 63/123,711, filed on Dec. 10, 2020.
Prior Publication US 2023/0330087 A1, Oct. 19, 2023
Int. Cl. A61K 31/496 (2006.01); A61K 9/00 (2006.01); A61P 9/04 (2006.01)
CPC A61K 31/496 (2013.01) [A61K 9/0053 (2013.01); A61P 9/04 (2018.01)] 9 Claims
 
1. A method of treating non-obstructive hypertrophic cardiomyopathy (HCM) in a subject, the method comprising providing to a subject having non-obstructive HCM a compound represented by formula (IX):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.